AU2018248961B2 - Assay to measure the potency of receptor-ligand interactions in nanomedicines - Google Patents

Assay to measure the potency of receptor-ligand interactions in nanomedicines Download PDF

Info

Publication number
AU2018248961B2
AU2018248961B2 AU2018248961A AU2018248961A AU2018248961B2 AU 2018248961 B2 AU2018248961 B2 AU 2018248961B2 AU 2018248961 A AU2018248961 A AU 2018248961A AU 2018248961 A AU2018248961 A AU 2018248961A AU 2018248961 B2 AU2018248961 B2 AU 2018248961B2
Authority
AU
Australia
Prior art keywords
antigen
cell
tcr
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018248961A
Other languages
English (en)
Other versions
AU2018248961A1 (en
Inventor
Pedro Santamaria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UTI LP
Original Assignee
UTI LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UTI LP filed Critical UTI LP
Publication of AU2018248961A1 publication Critical patent/AU2018248961A1/en
Application granted granted Critical
Publication of AU2018248961B2 publication Critical patent/AU2018248961B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
AU2018248961A 2017-04-07 2018-04-05 Assay to measure the potency of receptor-ligand interactions in nanomedicines Active AU2018248961B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483298P 2017-04-07 2017-04-07
US62/483,298 2017-04-07
PCT/IB2018/000510 WO2018185564A2 (en) 2017-04-07 2018-04-05 Assay to measure the potency of receptor-ligand interactions in nanomedicines

Publications (2)

Publication Number Publication Date
AU2018248961A1 AU2018248961A1 (en) 2019-10-31
AU2018248961B2 true AU2018248961B2 (en) 2024-06-20

Family

ID=63713282

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018248961A Active AU2018248961B2 (en) 2017-04-07 2018-04-05 Assay to measure the potency of receptor-ligand interactions in nanomedicines

Country Status (13)

Country Link
US (2) US20200057048A1 (https=)
EP (1) EP3607058A4 (https=)
JP (2) JP2020516594A (https=)
KR (1) KR20200004807A (https=)
CN (1) CN110945120B (https=)
AU (1) AU2018248961B2 (https=)
BR (1) BR112019021022A2 (https=)
CO (1) CO2019011018A2 (https=)
IL (1) IL269846A (https=)
MX (1) MX2019012058A (https=)
RU (1) RU2019135533A (https=)
SG (1) SG11201909290TA (https=)
WO (1) WO2018185564A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
ES3055030T3 (en) 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
EP3716949A4 (en) 2017-11-29 2022-05-18 UTI Limited Partnership Methods of treating autoimmune disease
CN112585162B (zh) * 2018-08-06 2025-01-28 基因医疗免疫疗法有限责任公司 Ha-1特异性t细胞受体及其用途
GB201906127D0 (en) * 2019-05-01 2019-06-12 Immutep S A Assays
EP3958892A4 (en) * 2019-05-23 2023-06-14 UTI Limited Partnership METHOD OF TREATMENT OF LIVER DISEASE
KR20220150276A (ko) * 2020-01-11 2022-11-10 시벡 바이오테크놀로지스, 엘엘씨 진핵생물로의 진핵생물-번역가능한 mRNA의 생산 및 전달을 위한 미생물 시스템
CN115917654A (zh) * 2020-04-21 2023-04-04 瑞泽恩制药公司 用于分析受体相互作用的方法和系统
WO2021148683A2 (en) * 2020-05-06 2021-07-29 Imcyse Sa Peptides and methods for the treatment of multiple sclerosis
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4211149A4 (en) * 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CA3232037A1 (en) * 2021-09-21 2023-03-30 Monash University Methods of treatment
CN113960003B (zh) * 2021-10-20 2023-10-24 吉林大学 基于dna银纳米簇和金纳米棒检测四环素的适配体传感器
US11873507B2 (en) * 2021-11-29 2024-01-16 Replicate Bioscience, Inc. Compositions and methods for expression of IL-12 and IL-1RA
EP4249062A1 (en) * 2022-03-24 2023-09-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
CN115125205A (zh) * 2022-06-14 2022-09-30 中国医学科学院生物医学工程研究所 一种修饰EpCAM抗体和/或CSV抗体的白细胞磁球及其制备方法
WO2024248042A1 (ja) * 2023-05-29 2024-12-05 国立大学法人 東京大学 ＭｕＳＫを標的とする新規化合物及びその用途
AU2024346292A1 (en) * 2023-09-22 2026-04-02 Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US707993A (en) 1901-05-16 1902-08-26 Clinton J Warren Machine for corking bottles.
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
AU3896699A (en) 1998-05-07 1999-11-23 Regents Of The University Of California, The Use of neglected target tissue antigens in modulation of immune responses
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
DE60226852D1 (de) 2001-03-13 2008-07-10 Novartis Ag Lentivirale verpackungskonstrukte
GB0417954D0 (en) * 2004-08-12 2004-09-15 Avidex Ltd Cellulat TCR ligand assay method
AU2008222678B2 (en) * 2007-03-07 2013-01-17 The General Hospital Corporation Compositions and methods for the prevention and treatment of autoimmune conditions
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
WO2010055510A2 (en) 2008-11-12 2010-05-20 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
CA2813064C (en) 2010-09-29 2021-06-01 Uti Limited Partnership Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US8809057B2 (en) * 2012-01-04 2014-08-19 Raytheon Bbn Technologies Corp. Methods of evaluating gene expression levels
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
JP6014440B2 (ja) 2012-09-26 2016-10-25 日立オートモティブシステムズ株式会社 移動物体認識装置
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
DK3220927T3 (en) * 2014-11-20 2022-02-14 Promega Corp Systems and methods for assessing modulators of immune checkpoints
EP3233903B1 (en) * 2014-12-19 2020-12-09 ETH Zürich Chimeric antigen receptors and methods of use
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
KR20260048600A (ko) * 2015-03-27 2026-04-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 변형된 t 세포 및 이의 제조 및 사용 방법
ES3055030T3 (en) * 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
HK1253694A1 (zh) * 2015-06-01 2019-06-28 Medigene Immunotherapies Gmbh T细胞受体文库
JP2018531593A (ja) * 2015-09-11 2018-11-01 アジェナス インコーポレイテッド 操作された宿主細胞及びそれらの使用方法

Also Published As

Publication number Publication date
JP2020516594A (ja) 2020-06-11
US20240201171A1 (en) 2024-06-20
BR112019021022A2 (pt) 2020-06-09
SG11201909290TA (en) 2019-11-28
CN110945120A (zh) 2020-03-31
AU2018248961A1 (en) 2019-10-31
MX2019012058A (es) 2019-11-11
WO2018185564A2 (en) 2018-10-11
WO2018185564A3 (en) 2019-01-03
EP3607058A4 (en) 2020-12-16
CA3059016A1 (en) 2018-10-11
KR20200004807A (ko) 2020-01-14
JP2024073459A (ja) 2024-05-29
IL269846A (en) 2019-11-28
RU2019135533A (ru) 2021-05-07
US20200057048A1 (en) 2020-02-20
CO2019011018A2 (es) 2019-10-21
CN110945120B (zh) 2025-04-18
EP3607058A2 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
AU2018248961B2 (en) Assay to measure the potency of receptor-ligand interactions in nanomedicines
US20240299536A1 (en) Nanoparticle compositions for sustained therapy
US20250051420A1 (en) RECOMBINANT pMHC CLASS II MOLECULES
KR101972291B1 (ko) 생체적합성, 생흡수성 나노구를 사용하는 자가면역 질병의 치료방법
CA3059016C (en) Assay to measure the potency of receptor-ligand interactions in nanomedicines
HK1252348B (en) Nanoparticle compositions for sustained therapy
RU2777115C2 (ru) РЕКОМБИНАНТНЫЕ МОЛЕКУЛЫ pMHC КЛАССА II
BR112017023853B1 (pt) Complexo, composições, seus usos e método in vitro ou ex vivo para a diferenciação de uma célula t ativada ou uma célula t de memória em uma célula tr1 produtora de il-10

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)